Trial · NCT01671449
S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer
NCT01671449, Phase 3, Completed, Min-Hee Ryu
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer. Trials, record NCT01671449. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01671449
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer
- NCT number
- NCT01671449
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 338 participants, actual
- Lead sponsor
- Min-Hee Ryu
- Conditions
- Gastric Cancer
- Interventions
- S-1, Cisplatin, Oxaliplatin
- First posted
- 2012-08-23
- Last updated
- 2015-11-30
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival | From date of randomization to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years | The primary endpoint of this study is progression-free survival. This is defined as the time from randomization to disease progression or death due to any cause. |
| Secondary | Overall survival | From date of randomization to death from any cause, assessed up to 3 years | Overall survival is defined as the time from randomization to death due to any cause. |
| Secondary | Response rate | Every 6 weeks | Response assessment will be performed according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 every 2 cycles (6 weeks) of treatment. |
| Secondary | Quality of life | Every 6 weeks | Quality of life of patient will be evaluated using EUROQOL(EQ-5D). Evaluation of quality of life will be performed every 2 cycles (6 weeks) from baseline to the end of treatment. |
| Secondary | Number of Adverse Events | Every 3 weeks | Monitoring for safety and toxicity will be performed every cycle (3 weeks) of chemotherapy and whenever patients have problems. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers42
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01671449
GET https://conductscience.org/api/trials/v1/NCT01671449/papers?page=2